Selective elimination of host cells harboring replication-competent human immunodeficiency virus reservoirs: a promising therapeutic strategy for HIV cure
Open Access
- 7 October 2021
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Chinese Medical Journal
- Vol. 134 (23), 2776-2787
- https://doi.org/10.1097/cm9.0000000000001797
Abstract
Many seminal advances have been made in human immunodeficiency virus (HIV)/AIDS research over the past four decades. Treatment strategies, such as gene therapy and immunotherapy, are yielding promising results to effectively control HIV infection. Despite this, a cure for HIV/AIDS is not envisioned in the near future. A recently published academic study has raised awareness regarding a promising alternative therapeutic option for HIV/AIDS, referred to as “selective elimination of host cells capable of producing HIV” (SECH). Similar to the “shock and kill strategy,” the SECH approach requires the simultaneous administration of drugs targeting key mechanisms in specific cells to efficiently eliminate HIV replication-competent cellular reservoirs. Herein, we comprehensively review the specific mechanisms targeted by the SECH strategy. Briefly, the suggested cocktail of drugs should contain (i) latency reversal agents to promote the latency reversal process in replication-competent reservoir cells, (ii) pro-apoptotic and anti-autophagy drugs to induce death of infected cells through various pathways, and finally (iii) drugs that eliminate new cycles of infection by prevention of HIV attachment to host cells, and by HIV integrase inhibitor drugs. Finally, we discuss three major challenges that are likely to restrict the application of the SECH strategy in HIV/AIDS patients.Keywords
This publication has 152 references indexed in Scilit:
- Reactivation of Latent HIV-1 by Inhibition of BRD4Cell Reports, 2012
- Redefining the Viral Reservoirs that Prevent HIV-1 EradicationImmunity, 2012
- Blocking HIV-1 entry by a gp120 surface binding inhibitorBioorganic & Medicinal Chemistry Letters, 2012
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor DolutegravirJournal of Virology, 2012
- Inhibition of autophagy by TAB2 and TAB3The EMBO Journal, 2011
- Beclin1 Controls the Levels of p53 by Regulating the Deubiquitination Activity of USP10 and USP13Cell, 2011
- HIV LatencyCold Spring Harbor Perspectives in Medicine, 2011
- Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-KinaseJournal of Biological Chemistry, 2010
- Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophagesThe Journal of cell biology, 2009
- Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)Journal of Virology, 2008